WallStSmart
MIST

Milestone Pharmaceuticals Inc

NASDAQ: MIST · HEALTHCARE · BIOTECHNOLOGY

$1.80
-1.10% today

Updated 2026-04-30

Market cap
$218.86M
P/E ratio
P/S ratio
141.57x
EPS (TTM)
$-0.75
Dividend yield
52W range
$1 – $3
Volume
2.1M

Milestone Pharmaceuticals Inc (MIST) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-9.7%
Last 4 quarters
Revenue YoY growth
+1331.5%
Most recent quarter
EPS YoY growth
+21.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+14.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+29.7%
2026-03-31
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-31$-0.15+6.3%$1.01$1.31+29.7%
2025-11-12$-0.12+25.0%$1.91$1.90-0.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.16$-0.15+6.3%$1.55M+1331.5%
2025-09-30$-0.16$-0.12+25.0%
2025-06-30$-0.18$-0.20-11.1%
2025-03-31$-0.20$-0.31-59.0%
2024-12-31$-0.15$-0.19-26.7%$108000.00-112.4%
2024-09-30$-0.16$-0.14+10.9%
2024-06-30$-0.19$-0.14+26.3%
2024-03-31$-0.26$-0.21+19.2%$-868002.00-186.8%
2023-12-31$-0.31$-0.32-3.2%$-868002.00
2023-09-30$-0.38$-0.35+7.9%
2023-06-30$-0.39$-0.37+5.1%
2023-03-31$-0.40$-0.35+12.5%$1.00M

Frequently asked questions

Has Milestone Pharmaceuticals Inc beaten earnings estimates?
Milestone Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -9.7% over the last 4 quarters.
How does MIST stock react to earnings?
MIST stock has moved an average of +14.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Milestone Pharmaceuticals Inc's revenue growth rate?
Milestone Pharmaceuticals Inc reported year-over-year revenue growth of +1331.5% in its most recent quarter, with EPS growing +21.1% year-over-year.